Swiss National Bank raised its position in Clovis Oncology, Inc. (NASDAQ:CLVS) by 18.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,450 shares of the biopharmaceutical company’s stock after buying an additional 12,000 shares during the period. Swiss National Bank owned 0.17% of Clovis Oncology worth $7,158,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 758 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 1,168 shares in the last quarter. Legato Capital Management LLC acquired a new position in Clovis Oncology in the second quarter valued at about $220,000. Bank of Montreal Can boosted its position in Clovis Oncology by 284.9% in the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 2,000 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 98.94% of the company’s stock.
Clovis Oncology, Inc. (CLVS) opened at 69.46 on Friday. Clovis Oncology, Inc. has a 12 month low of $25.50 and a 12 month high of $99.45. The firm’s market capitalization is $3.40 billion. The stock’s 50 day moving average is $74.21 and its 200-day moving average is $68.78.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.02). The firm had revenue of $14.62 million for the quarter, compared to the consensus estimate of $13.07 million. During the same quarter in the prior year, the firm posted ($2.07) EPS. The company’s quarterly revenue was down 32.5% compared to the same quarter last year. Equities analysts anticipate that Clovis Oncology, Inc. will post ($7.56) earnings per share for the current fiscal year.
CLVS has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, May 19th. BidaskClub upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Cann restated a “hold” rating on shares of Clovis Oncology in a research report on Monday, September 11th. Evercore ISI initiated coverage on shares of Clovis Oncology in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 price target on the stock. Finally, Royal Bank Of Canada initiated coverage on shares of Clovis Oncology in a research report on Thursday. They issued a “sector perform” rating and a $81.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Clovis Oncology has a consensus rating of “Buy” and a consensus target price of $84.91.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $70.05, for a total value of $210,150.00. Following the sale, the insider now directly owns 194,583 shares in the company, valued at approximately $13,630,539.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James C. Blair sold 18,450 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the sale, the director now owns 2,185 shares in the company, valued at $171,762.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,450 shares of company stock worth $1,935,185. 17.40% of the stock is currently owned by corporate insiders.
WARNING: This piece of content was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://stocknewstimes.com/2017/09/16/clovis-oncology-inc-clvs-holdings-boosted-by-swiss-national-bank.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.